Clinical UpdatesBYQLOVICataract surgery
Clobetasol Propionate Ophthalmic Suspension 0.05%: A New Therapeutic Milestone in Post-Cataract Surgery Inflammation and Pain Management
By MedXY|May 12, 2026
This review synthesizes clinical evidence for CPN 0.05% (BYQLOVI®), highlighting its rapid efficacy, superior pain resolution, and favorable safety profile compared to traditional ocular steroids following cataract surgery.